3 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
3 - IMAC Holdings, Inc. (0001729944) (Issuer)
3 - IMAC Holdings, Inc. (0001729944) (Issuer)
3 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
4 - IMAC Holdings, Inc. (0001729944) (Issuer)
Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i
Golden, Colorado, June 27, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC:THER) ("Theralink" or the "Company"), a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. (NASDAQ:BACK), today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company's President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink's Chief Medical Officer. "I am very excited to hand the reins to Faith as we take the strategic step to merge wit
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,
Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) ("Theralink"), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per s
BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations. "We are excited for the Curis team to support and grow the business going forward while we return our focus to non-surgical medical care for a person's optimal orthopedic function, stability, and mobility," said Jeff Ervin, Chief Executive Officer of IMAC. In addition to the sale of The BackSpace, the Company's Chief Operating Officer, Dr. Ben Lerner, ann
NT 10-Q - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K/A - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
8-K - IMAC Holdings, Inc. (0001729944) (Filer)
SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)
FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ("IMAC" or the "Company") (NASDAQ:BACK) today announced that it has received an exception from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"). This exception extends the deadline for the Company to file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q") until February 17, 2025. The delay in filing is primarily due to complexities in preparing our financial statements for the second quarter as a result of events occurring during the period ended June 30, 2024 and certain staffing cha
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC Holdings" or the "Company"), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC ("Ignite Proteomics"). This launch follows IMAC Holdings' strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study "Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer", demonstra
FRANKLIN, TN, Aug. 23, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. ("IMAC" or the "Company") (NASDAQ:BACK) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on August 21, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Commission (
Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC:THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (NASDAQ:BACK), announce that the companies have responded to the SEC's first round of comments on the jointly filed form S-4. A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition. The Compa
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC:THER) ("Theralink"), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute (Inova) is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova's Molecular Tumor Board (MTB)-based treatment decisioning making for cancer patients. The partnership involves the integration of the
-SEC Filing
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Aon posted adjusted earnings of $5.66 per share, missing market estimates of $5.91 per share. The company's sales came in at $4.070 billion versus expectations of $4.126 billion, according to data from Benzinga Pro. Aon shares dipped 7.4% to $283.19 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) shares jumped 73.3% to $1.2475 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa. Pineapple Energy Inc. (NASDAQ
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 61.4% to $1.17 during Friday's regular session. The company's market cap stands at $5.1 million. Agenus (NASDAQ:AGEN) shares rose 32.53% to $11.0. The market value of their outstanding shares is at $230.4 million. Sunshine Biopharma (NASDAQ:SBFM) shares increased by 31.18% to $1.06. The company's market cap stands at $1.0 million. Cullinan Therapeutics (NASDAQ:CGEM) stock moved upwards by 30.85% to $25.19. The company's market cap stands at $1.0 billion. ImmunityBio (NASDAQ:IBRX) shares rose 27.2% to $6.5. The market value of their outstanding shares is at $4.4 billion. Zura Bio (NASDAQ:ZURA) shares increased by 25.69% to $4.55.
Gainers Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Processa Pharma (NASDAQ:PCSA) stock moved upwards by 43.18% to $2.32. The market value of their outstanding shares is at $6.6 million. Akso Health Group (NASDAQ:AHG) shares moved upwards by 29.87% to $1.0. The market value of their outstanding shares is at $109.5 million. Eyenovia (NASDAQ:EYEN) shares increased by 22.87% to $0.72. The company's market cap stands at $33.9 million. Predictive Oncology (NASDAQ:POAI) stock increased by 21.64% to $1.63. The company's market cap stands at $6.6 million. IMAC Hldgs (NASDAQ:BAC
IMAC Hldgs's (NYSE:BACK) short percent of float has risen 1447.53% since its last report. The company recently reported that it has 880 thousand shares sold short, which is 84.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest
Shares of Skillsoft Corp. (NASDAQ:SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. Skillsoft posted adjusted loss of $3.09 per share, versus market estimates of $3.27 per share. The company’s quarterly sales came in at $137.540 million versus expectations of $141.897 million. Skillsoft shares dipped 26.7% to $6.74 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers WiSA Technologies, Inc. (NASDAQ:WISA) jumped 85% to $3.2379 after the company announced a 5-year WiSA E licensing agreement with an HDTV/PTV brand. Palisade Bio, Inc. (NASDAQ:PALI)
Gainers Eliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. Rallybio (NASDAQ:RLYB) stock increased by 49.07% to $2.43. The company's market cap stands at $91.8 million. Alpine Immune Sciences (NASDAQ:ALPN) shares rose 36.62% to $64.27. The company's market cap stands at $4.2 billion. IMAC Hldgs (NASDAQ:BACK) stock increased by 22.41% to $3.44. The market value of their outstanding shares is at $3.9 million. Healthcare Triangle (NASDAQ:HCTI) shares rose 15.3% to $1.77. The market value of their outstanding shares is at $8.2 million. Lipocine (NASDAQ:LPCN) stock ros
Gainers Rallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% to $46.0. The market value of their outstanding shares is at $2.5 billion. Biophytis (NASDAQ:BPTS) stock rose 9.49% to $0.37. The company's market cap stands at $4.2 million. IMAC Hldgs (NASDAQ:BACK) shares rose 7.35% to $3.02. The company's market cap stands at $3.4 million. Relay Therapeutics (NASDAQ:RLAY) stock moved upwards by 7.1% to $7.39. The company's market cap stands at $969.4 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 6.43% to $2.48. The company's market ca
Gainers Stoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press release, Q4 earnings came out yesterday. OpGen (NASDAQ:OPGN) shares moved upwards by 77.6% to $0.84. The market value of their outstanding shares is at $8.4 million. ABVC BioPharma (NASDAQ:ABVC) stock increased by 45.71% to $1.53. The market value of their outstanding shares is at $16.1 million. Mesoblast (NASDAQ:MESO) shares moved upwards by 32.27% to $2.91. The market value of their outstanding shares is at $295.3 million. Praxis Precision Medicine (NASDAQ:PRAX) shares increased by 21.38% to